Jim Winkler

Optimization of triarylimidazoles for Tie2: Influence of conformation on potency

Neil W. Johnson, M.A. Semones, Jerry L. Adams et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 25 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +8

Preclinical development of ARRY-142886, a potent and selective MEK inhibitor

Eli Wallace, Tammie C. Yeh, Joe Lyssikatos et al. · Cancer Research · 2004 · 18 citations

Medicine, Cancer Biology, Pharmacology +15

ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2

Greg Miknis, Eli Wallace, Joe Lyssikatos et al. · Cancer Research · 2005 · 14 citations

Medicine, Medicinal Chemistry, Pharmacology +16

<i>In Vivo</i> Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab.

P. Lee, Deborah Anderson, Karyn Bouhana et al. · Cancer Research · 2009 · 11 citations

Medicine, Oncology, Pharmacology +17

ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors

Richard Woessner, Chris Corrette, Shelley Allen et al. · Cancer Research · 2007 · 10 citations

Medicine, Oncology, Pharmacology +17